Tri K. Nguyen

Medicine · Health Sciences

8h-index552citations17works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(9), Endoplasmic Reticulum Stress and Disease(6), Eosinophilic Disorders and Syndromes(5), Chronic Lymphocytic Leukemia Research(4), Advanced Breast Cancer Therapies(3)

Publications17 total

Data from Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
2023Open Access
Data from Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
2023Open Access
Supplementary Figures 1 - 4 from Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
2023Open Access
Supplementary Figures 1 - 4 from Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
2023Open Access
Corrigendum to “Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl” [Leuk. Res. 30 (2006) 1263–1272]
Leukemia Research·2019
Abstract 2686: The CDK inhibitor dinaciclib (SCH727965) inhibits the unfolded protein response (UPR) through a CDK1- and CDK5-dependent mechanism
Cancer Research·2014
Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
Molecular Cancer Therapeutics·2013· 40 citedOpen Access
Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cells <i>in vitro</i> and <i>in vivo</i>
Cancer Research·2011· 1 cited
Abstract 5412: Synergistic interactions between histone deacetylase inhibitors and aurora kinase inhibitor KW2449 Ph+ cells
Cancer Research·2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
Leukemia Research·2010· 29 cited
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Blood·2008· 63 citedOpen Access
Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate.
Blood·2007· 3 cited
The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation
Molecular Pharmacology·2007· 60 cited
The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress
Molecular and Cellular Biology·2007· 248 citedOpen Access
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Blood·2007· 55 citedOpen Access
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate
Clinical Cancer Research·2006· 22 cited
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl
Leukemia Research·2006· 31 cited

Frequent Co-authors

Steven Grant(17), Paul Dent(9), Mohamed Rahmani(4), Yun Dai(4), Shuang Chen(2), Charis A. Venditti(2), Girija Dasmahapatra(2), Lora B. Kramer(2), Eric Maynard Davis(1), Timothy Ryan Crabtree(1), Joseph Habibi(1), Xin‐Yan Pei(1), Hisashi Harada(1), Nicholas Jordan(1), Jonathan W. Friedberg(1), Richard I. Fisher(1), Ning Gao(1), Amie S. Corbin(1), Brian Druker(1), Elisa Attkisson(1)